Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP9 | Q86TI2 | 12/20 | 1.00 |
| ▸ | DPP8 | Q6V1X1 | 10/20 | 1.00 |
| ▸ | DPP4 | P27487 | 7/20 | 1.00 |
| ▸ | DPP7 | Q9UHL4 | 7/20 | 1.00 |
| ▸ | PITRM1 | Q5JRX3 | 1/20 | 0.63 |
| ▸ | NAMPT | P43490 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21746415 | 1.00 | DPP9 (1.00) | DPP9DPP8DPP4DPP7PITRM1 | |
| SCHEMBL21746934 | 0.84 | DPP9 (1.00) | DPP9DPP8DPP4DPP7PITRM1 | |
| SCHEMBL21746935 | 0.84 | DPP9 (1.00) | DPP9DPP8DPP4DPP7PITRM1 | |
| SCHEMBL4122448 | 0.82 | DPP8 (0.68) | DPP9DPP8DPP4DPP7 | |
| SCHEMBL21156231 | 0.78 | DPP9 (1.00) | DPP9DPP8DPP4DPP7PITRM1 | |
| SCHEMBL21156683 | 0.78 | DPP9 (1.00) | DPP9DPP8DPP4DPP7PITRM1 | |
| SCHEMBL8401777 | 0.77 | DPP9 (0.62) | DPP9DPP8DPP4DPP7PITRM1 | |
| SCHEMBL21746978 | 0.77 | DPP9 (1.00) | DPP9DPP8DPP4DPP7PITRM1 | |
| SCHEMBL24958752 | 0.77 | DPP9 (1.00) | DPP9DPP8DPP4DPP7 | |
| SCHEMBL24958790 | 0.75 | DPP9 (1.00) | DPP9DPP8DPP4DPP7PITRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230372372-A1 | COMBINATION THERAPIES USING CASPASE-1 DEPENDENT ANTICANCER AGENTS AND PGE2 ANTAGONISTS | TRUSTEES OF TUFTS COLLEGE | 2023-11-23 | — | — | US | disclosed |
| US-20230372372-A1 | COMBINATION THERAPIES USING CASPASE-1 DEPENDENT ANTICANCER AGENTS AND PGE2 ANTAGONISTS | TRUSTEES OF TUFTS COLLEGE | 2023-11-23 | — | — | US | disclosed |
| US-11583516-B2 | Dash inhibitors, and uses related thereto | TRUSTEES OF TUFTS COLLEGE (US) | 2023-02-21 | — | — | US | disclosed |
| US-11559537-B2 | Combination therapies using caspase-1 dependent anticancer agents and PGE2 antagonists | TRUSTEES OF TUFTS COLLEGE (US) | 2023-01-24 | — | — | US | disclosed |
| US-20200054655-A1 | COMBINATION THERAPIES USING CASPASE-1 DEPENDENT ANTICANCER AGENTS AND PGE2 ANTAGONISTS | TRUSTEES OF TUFTS COLLEGE | 2020-02-20 | — | — | US | disclosed |
| US-20190209525-A1 | DASH INHIBITORS, AND USES RELATED THERETO | TRUSTEES OF TUFTS COLLEGE | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11583516-B2 | Dash inhibitors, and uses related thereto | PCNA, CD2BP2, CCNO | DPP9 174/4885DPP8 92/4885DPP4 421/4885 |
| US-11559537-B2 | Combination therapies using caspase-1 dependent anticancer agents and PGE2 antagonists | CASP1, CASP2, APAF1 | DPP9 1286/4885DPP8 904/4885DPP4 1251/4885 |
| US-20230372372-A1 | COMBINATION THERAPIES USING CASPASE-1 DEPENDENT ANTICANCER AGENTS AND PGE2 ANTAGONISTS | CASP1, CASP2, APAF1 | DPP9 1286/4885DPP8 904/4885DPP4 1251/4885 |
| US-20200054655-A1 | COMBINATION THERAPIES USING CASPASE-1 DEPENDENT ANTICANCER AGENTS AND PGE2 ANTAGONISTS | CASP1, CASP2, APAF1 | DPP9 1286/4885DPP8 904/4885DPP4 1251/4885 |
| US-20190209525-A1 | DASH INHIBITORS, AND USES RELATED THERETO | CD2BP2, PCNA, CD2 | DPP9 155/4885DPP8 94/4885DPP4 402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.